By Fineline Cube 
China-based Sunshine Lake Pharma Co., Ltd has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKEX), with the unit price and other key details yet to be announced. The exclusive sponsor for this IPO is CICC, a leading financial institution.
Established Pharmaceutical Company with a Diverse Portfolio
Founded in 2003, Sunshine Lake Pharma has established itself as a comprehensive pharmaceutical company with a business model encompassing drug research and development (R&D) and commercialization. The company’s product pipeline is diverse, including innovative drugs, modified drugs, generic drugs, and biosimilars, targeting areas such as infection, chronic diseases, and tumors. Sunshine Lake Pharma prides itself on its leading R&D platforms that cover the full lifecycle of chemical and biological drugs, globally aligned manufacturing facilities, and a robust global sales network. The company also engages with advanced technologies such as AIDD, small nucleic acid, and ADC.
Global Footprint and Market Performance
As of June 30, 2024, Sunshine Lake Pharma has a global portfolio of 147 approved drugs and over 100 investigational drug candidates, including 45 Category 1 products. Among these, 3 innovative drugs are under marketing review in China, and 10 are in Phase II/III stages. The company’s infection sector has seen particular success, with its top-selling product KeWei (oseltamivir) capturing 64.8% of the market share in China in 2023. Sunshine Lake Pharma operates the world’s largest oseltamivir manufacturing facility at its Yidu plant and maintains an extensive sales network that spans China, Europe, and North America.-Fineline Info & Tech